Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 14/20 | 0.41 |
| ▸ | AKT2 | P31751 | 7/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.35 |
| ▸ | FECH | P22830 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538608 | 0.86 | AKT1 (0.42) | AKT1AKT2AKT3FECH | |
| SCHEMBL2029645 | 0.86 | TACR3 (0.34) | AKT1AKT2AKT3HPGDALDH1A1 | |
| SCHEMBL1352326 | 0.85 | AKT1 (0.42) | AKT1AKT2AKT3FECHPSMB5 | |
| SCHEMBL1351893 | 0.85 | AKT1 (0.43) | AKT1AKT2 | |
| SCHEMBL1351858 | 0.84 | AKT1 (0.40) | AKT1AKT2AKT3FECH | |
| SCHEMBL4299454 | 0.82 | AKT1 (0.38) | AKT1AKT2AKT3FECH | |
| SCHEMBL1350451 | 0.81 | AKT1 (0.41) | AKT1AKT2AKT3FECH | |
| SCHEMBL1352098 | 0.81 | AKT1 (0.46) | AKT1AKT2AKT3FECHPSMB5 | |
| SCHEMBL1352537 | 0.81 | AKT1 (0.41) | AKT1AKT2AKT3FECH | |
| SCHEMBL3783328 | 0.80 | AKT1 (0.47) | AKT1AKT2AKT3FECHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| EP-2299825-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | AKT1 3/4885AKT2 5/4885AKT3 9/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885AKT3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.